RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Theranexus Stock

Theranexus EBIT 2024

Theranexus EBIT

-7.21 M EUR

Ticker

ALTHX.PA

ISIN

FR0013286259

WKN

A2H6LX

In 2024, Theranexus's EBIT was -7.21 M EUR, a -5.67% increase from the -7.64 M EUR EBIT recorded in the previous year.

The Theranexus EBIT history

YEAREBIT (undefined EUR)
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-

Theranexus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Theranexus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Theranexus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Theranexus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Theranexus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Theranexus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Theranexus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Theranexus’s growth potential.

Theranexus Revenue, EBIT and net profit per share

DateTheranexus RevenueTheranexus EBITTheranexus Net Income
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined

Theranexus stock margins

The Theranexus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theranexus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theranexus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Theranexus's sales revenue. A higher gross margin percentage indicates that the Theranexus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Theranexus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Theranexus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Theranexus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Theranexus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Theranexus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Theranexus Margin History

Theranexus Gross marginTheranexus Profit marginTheranexus EBIT marginTheranexus Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Theranexus Aktienanalyse

What does Theranexus do?

Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Theranexus's EBIT

Theranexus's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Theranexus's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Theranexus's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Theranexus’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Theranexus stock

How much did Theranexus achieve in EBIT for the current year?

In the current year, Theranexus has achieved an EBIT of -7.21 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Theranexus.

How has the EBIT of Theranexus developed in recent years?

The EBIT of Theranexus has increased by -5.674% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Theranexus?

The EBIT of Theranexus is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Theranexus pay?

Over the past 12 months, Theranexus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theranexus is expected to pay a dividend of 0 EUR.

What is the dividend yield of Theranexus?

The current dividend yield of Theranexus is .

When does Theranexus pay dividends?

Theranexus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theranexus?

Theranexus paid dividends every year for the past 0 years.

What is the dividend of Theranexus?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theranexus located?

Theranexus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theranexus from 12/24/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Theranexus pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Theranexus in the year 2023?

In the year 2023, Theranexus distributed 0 EUR as dividends.

In which currency does Theranexus pay out the dividend?

The dividends of Theranexus are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Theranexus

Our stock analysis for Theranexus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.